Human adipose tissue-derived stem cells (hASCs) are considered as an attractive source of regenerative stem cells, mainly because of their higher proliferation rate, more accessibility and hepatocyte like properties as compared to mesenchymal stem cells isolated from other tissues. Numerous studies have described the beneficial use of adipose tissue-derived stem cells for generating hepatocyte-like cells. However, due to the lack of appropriate culture conditions, most of the produced cells exhibit poor functionality. The aim of the present study was to establish a new protocol for the efficient hepatic differentiation of hASCs. Materials and Methods: hASCs were cultured in hepatic differentiation medium containing fibroblast growth factor 4, hepatocyte growth factor, dexamethasone and oncostatin M using a three-step protocol up to 21 days. Then, the functionality of the treated cells was evaluated by analyzing specific hepatocyte genes and biochemical markers at various time points. Results: A significant upregulation in albumin, alpha-fetoprotein, cytokeratin 18 and hepatocyte nuclear factor-4α expressions was observed in differentiated cells relative to day 1 of differentiation protocol. Moreover, the finding of glycogen deposits increased urea production and positive immunofluorescence staining for albumin and alpha-fetoprotein in hepatocyte-like cells suggesting that most of the cells differentiate into hepatocyte-like cells. Conclusions: Our report has provided a simple protocol for differentiation of hASCs into more functional hepatocyte-like cells.
Introduction
The liver is a significant organ in the human body performing vital functions including detoxification, metabolism, and hormone balance. In addition to these roles, liver is known to possess a remarkable regenerative capacity. However, this ability is impaired following numerous liver failures such as cirrhosis for which liver transplantation is the only available clinical option [1] . Indeed, due to discrepancies associated with liver transplantation, it is of utmost importance to find alternative strategies for the treatment of end-stage liver disorders [2] .
In this context, cell-based therapy has become the focus of intense investigation in recent years [3] . Therefore, various kinds of stem cells have been studied to examine their clinical applications in regenerative medicine [4] . To date, there are numerous studies describing the beneficial use of mesenchymal stem cells (MSCs) for liver cell therapy, mainly because of their multipotent potential, lack of ethical concerns, and risk of rejection [5, 6] . MSCs can be isolated from different kinds of tissues including bone marrow (the first known tissue as a source of MSCs) [7] , umbilical cord blood, amniotic fluid as well as adipose tissue [8] . Of particular interest to researchers are the human adipose tissuederived stem cells (hASCs) which for the first time were isolated and described by Zuk et al.
In addition to their multilineage potential [9] , hASCs have been reported to exhibit higher proliferation rate, more accessibility and hepatocyte like properties [10] as compared to MSCs isolated from other tissues.
There are an increasing number of studies offering ASCs as an attractive candidate for generating hepatocyte-like cells. These studies have provided support for the use of a combination of growth factors and inductive agents to induce ASCs toward hepatic lineage [11] [12] [13] [14] [15] . However, most of the produced hepatocyte-like cells exhibit poor functionality, mainly due to the lack of appropriate induction conditions.
Developmental studies have uncovered a number of transcription factors and regulators as being implicated in hepatocyte differentiation [16] .
In this regard, fibroblast growth factors (FGFs) have been identified as being involved in early development and organogenesis [17, 18] . Of particular importance is FGF4 because of its involvement in hepatic induction [16, 19] as well as its role in liver regeneration [20] . In addition, it has been reported that MSCs pretreated with FGF4 in combination with hepatocyte growth factor (HGF) is able to reduce liver fibrosis and improve liver function in CCl4 induced mice [21] . Similar results have also been described upon using of FGF4 transduced bone marrow MSCs (BM-MSCs) in the cirrhotic liver model [22] .
Recently, using a combination of inductive agents including HGF, oncostatin M, and dexamethasone, we have differentiated hASCs into hepatocyte-like cells [23] 
Materials and Methods
Isolation and culture of hASCs hASCs were isolated from human lipoaspirates as described previously [23] . Briefly, lipoaspirates were digested using 0.075% collagenase I (Sigma-Aldrich, USA) at 37ºC for 30 min. Finally, the extracted cells were suspended in Dulbecco's modified Eagle's medium (DMEM) (Gibco, USA) containing 10% fetal bovine serum (FBS) (Gibco, USA), and 1% penicillin/streptomycin (SigmaAldrich, USA) and incubated in a humidified atmosphere at 37º C with 5% CO2.
In vitro hepatic differentiation of hASCs
To induce hepatic differentiation of hADSCs, a three-step procedure was used (Fig. 1A] Finally, 2 -ΔΔCt method was applied to calculate relative quantification of gene expression.
Immunofluorescence Staining
After fixation with 4% paraformaldehyde solution for 10 min at room temperature, the cells were permeabilized using 0.2% Triton X- per each treatment were considered for quantification of data [24] . In addition, all images were taken with exactly the same acquisition parameters including exposure time, gamma and saturation. Finally, image J software (version 1.42 V, NIH, USA) was used for quantification.
Hepatic functional tests

Glycogen staining
At day 21, the cells were evaluated for detection of glycogen deposit using periodic acid-schiff (PAS) staining. Firstly, the cells were fixed with 4% paraformaldehyde solution for 10 min, followed by oxidation using 1% periodic acid for 5 min. After washing with PBS, the cells were treated with Schiff's reagent (SigmaAldrich, USA) for 15 min. and counterstained using hematoxylin. Finally, the cells were visualized under an inverted microscope [23] .
Urea production
Urea concentrations were measured in the culture media of induced ASCs at different time points (on days 1, 7, 14, and 21). First, the cells were incubated in a culture medium containing 3mM NH4CL for 24h at 37ºC.
After collecting the supernatants, urea production was evaluated with a colorimetric assay kit (Zistchem, Iran) following the manufacturer's instruction. As a negative control, untreated hASCs were used and the amount of urea was normalized to the number of cells in each well [23] . This protocol was approved by Hormozgan University of Medical Sciences Ethics Committee.
Statistical analysis
The data are expressed as mean±SD. One wayanalysis of variance followed by Dunnett post Hep G2 cells were used, respectively.
Results
Morphological
As illustrated in Fig. 2A (Fig. 2E) . In addition, the expression of albumin and alpha-fetoprotein genes were further confirmed at protein level. Consistent with the expression of mentioned genes, the treated cells stained positive for both alphafetoprotein (Fig. 3A) and albumin (Fig. 4A) (Figs. 3, 4) . (Fig. 5A) .
In addition to these results, metabolic function of hepatocyte-like cells was also evaluated using urea assay at various stages of and continued to increase gradually with a maximum level to 17 mg/dl/50000 cells (p<0.01) compared to day 1 (Fig. 5B) . Fig. 5 . Functional assays of hepatocyte-like cells. A: Glycogen storage ability was detected using periodic acid-schiff staining which showed more positive cells in hepatocyte-like cells compared to untreated hASCs. B: A significant increase in urea production was detected in hepatocyte-like cells at day 14 and day 21 relative to day 1. The data are shown as mean±SD in three independent experiments (n=3). *p <0.05, **p <0.01, ***p <0.001 relative to day 1.
Discussion
As it has been extensively reported, ASCs possess the potential to differentiate into hepatocyte-like cells using a cocktail of growth factors and inductive agents [11] [12] [13] 15] . Interestingly, the expression of several hepatocyte-specific markers in naïve hASCs shows them to become one of the most attractive sources for cell-based therapy of liver diseases [10] . Whereas these findings are exciting, the function of the generated hepatocyte-like cells is often at a far lower level than a real hepatocyte mainly due to using inefficient induction conditions. We FGFs, secreted from the cardiac mesoderm, are known to be involved in early liver development [18] . In this regard, it has been well documented that FGFs are required for albumin expression and eventually hepatic induction at early somatic stages of development [25] . Of particular interest is FGF4, a member of FGF superfamily, acting as a mitogenic, angiogenic, and survival factor and involving in cell proliferation and differentiation [26] . Notably, the striking role of FGF4 in enrichment and propagation of hepatic progenitors has been reported [27] . In this context, it is important to mention that growth factors and regulators used in this study are known to be involved in development and differentiation of hepatocyte.
In addition to acting as a hepatocyte mitogen, HGF is also required for hepatoblast migration and proliferation [28, 29] . As mentioned before, FGFs exert a major influence on hepatic specification and also promote liver bud growth [25, 27] . Moreover, it is well established that oncostatin M, secreted by haematopoietic cells in liver, promotes hepatocyte differentiation, acting in collaboration of HGF and glucocorticoid hormones [30] . 
Conclusion
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